To improve the lives of patients affected by transthyretin amyloidoses through innovative therapeutic approaches.
Polyneuropathy and CNS Angiopathy
What is happening in our universe.
BSIM has attended the 2nd European ATTR amyloidosis Meeting for Doctors and Patients
BSIM Therapeutics is awarded a United States Patent (Patent #10,377,729) for one of its promising technologies in the stabilization of transthyretin (TTR)
Results published in Amyloid, The Journal, show that one of the technologies developed by BSIM Therapeutics stabilizes transthyretin in the cerebrospinal fluid and in the vitreous humor.
BSIM Therapeutics was one of the 25 companies selected for participation in the Accelerator Program of the European project Invest Horizon The kick-off event took place from June 3rd to 7th, 2019, in Paris.
By continuing to browse the site, you expressly agree that cookies will be stored on your computer to help measure statistics of visits and improve the quality of the contents offered.Learn more